Innocan Pharma Corporation INNPF INNO IP released its financial results for the three months ended March 31, 2023, revealing revenue of $1.6 million, an increase of 500%, compared to $260,000 in the first quarter of 2022. This increase in revenue growth is mainly due to the increased sales of Innocan's subsidiary, B.I. Sky Global Ltd.
Q1 2023 Financial Highlights
-
Gross Profit was $1.4 million, an increase of 1656% compared to $78,000 in the quarter ended March 31, 2022.
-
Gross profit margin was 87.8% compared to 30% in Q1 2022.
-
Operating loss was $1.3 million compared to $1.8 million in Q1 2022.
-
Total comprehensive loss was $1.2 million compared to $729,000 in Q1 2022.
-
The company's cash balance stood at approximately $4.1 million as of March 31, 2023, representing an approximate 17% decrease compared to approximately $4.9 million at the end of the prior year, due to continued investments in the company's strategic goals, which resulted in a number of meaningful milestones.
"We delivered encouraging results in the first quarter, including growth in revenue year-over-year. "We are confident in our long-term outlook" stated Iris Bincovich, CEO of Innocan, "we continue our strategic investments in cutting-edge science and innovation, while also delivering revenues from our consumer wellness activities".
Photo by Mackenzie Marco on Unsplash
Related News
Innocan Pharma FY22 Revenue Grows 1205% To $2.6M, Here Is What You Need To Know
Can Liposomal CBD Injection Help Dogs With Polyarthritis? Innocan Pharma Reports Clinical Success
Innocan Pharma Q3 Revenue Grows 700% YoY, Here Is What You Need To Know
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.